Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immunoprecise Antibodies Ltd IPA

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.


NDAQ:IPA - Post by User

Comment by cleareyeon Oct 14, 2021 3:19pm
164 Views
Post# 34006528

RE:At-The-Market Facility of up to US$50 Million

RE:At-The-Market Facility of up to US$50 MillionI prefer these ATM's to the usual raising cash through other stock purchase / options purchase schemes. They allow the company to raise cash without the one-day fanfare and usual drop in share-price that goes along with financing by other means.

If the company continues to have good cash flow it means that this ATM will not be needed. If they need a top-up some time then the company will not be subject to the usual downward manipulation and or downward loss due to "money" taking options and then shorting the stock based on the fact that the options exist to allow them to recoup at anytime.

So, good for IPA, and good for shareholders in my mind.

cleareye.
<< Previous
Bullboard Posts
Next >>